Login

Pfizer IGLC and BMS Corporate Giving Release an RFP in Cardiovascular Therapies

09 May 2017 9:59 AM | Jim Ranieri (Administrator)

Pfizer and Bristol-Myers Squibb (BMS) are working together on grants in support of innovative cardiovascular therapies. The goal of these grants is to improve patient care and outcomes through therapy innovation.

PLEASE NOTE: Responses to the RFP listed below should be made through the Bristol-Myers Squibb Grants and Giving website: 

http://www.bms.com/responsibility/grantsandgiving/support/pages/default.aspx

Request for Proposals (RFP)
Eliminating Barriers to Innovate Cardiovascular Therapies
to Improve Patient Care and Outcomes

Date RFP Issued: May 1, 2017

Clinical Area: Cardiovascular

Link to full RFP:  Eliminating Barriers to Innovate Cardiovascular Therapies to Improve Patient Care and Outcomes

Due Date: June 28, 2017

Geographic Scope: United States​

Specific Area of Interest: Chronic disease is the leading cause of death and disability in the United States. Accessing affordable treatments is vital for all Americans. There are many factors that may limit both patient and provider ability to access the newest and most innovative therapies including restrictive formularies, step therapy, non-medical switching, cost and cumbersome administrative processes including prior authorization and tier exception processes. The strategies employed to address these barriers may include

·         Gaining an understanding of barriers from each stakeholder’s point of view (HCP, Patient, administrative staff, caregivers, others)

·         Developing best practices that can inform advocacy organizations and medical societies, including the role each could play in the evolving access landscape

Questions regarding this RFP should be directed to nicole.peterson@bms.com.

Powered by Wild Apricot Membership Software